Provention Bio

$12.58
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.11 (-0.86%) Today
-$0.14 (-1.10%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Provention Bio and other stocks, options, and ETFs commission-free!

About PRVB

Provention Bio, Inc. Common Stock, also called Provention Bio, is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapeutics and solutions. Its products include PRV-031 for the interception of type 1 diabetes (T1D); PRV-015 for the treatment of gluten-free diet non-responding celiac disease; PRV-6527 for Crohn’s disease; PRV-3279 for the treatment of lupus; and PRV-101 for the prevention of acute coxsackie virus B (CVB), and the prevention of type 1 diabetes (T1D) onset. The company was founded by Francisco Leon and Ashleigh Palmer on October 4, 2016 and is headquartered in Lebanon, NJ. The listed name for PRVB is Provention Bio, Inc. Common Stock.

CEO
Ashleigh W. Palmer
Employees
19
Headquarters
Red Bank, New Jersey
Founded
2016
Market Cap
869.56M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
808.67K
High Today
$13.50
Low Today
$12.25
Open Price
$12.93
Volume
1.19M
52 Week High
$20.05
52 Week Low
$4.72

PRVB Earnings

-$0.58
-$0.30
-$0.02
$0.26
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
-$0.50 per share
Actual
-$0.58 per share
Replay Earnings Call

You May Also Like

ASOMY
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure